AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37453737
Drug: Abatacept monotherapy
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept monotherapy
Trial: 35248272
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both MT interventions
Trial: 34105177
Drug: Casimersen (4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casimersen (4, 10, 20, and 30 mg/kg weekly infusions)
Trial: 35193046
Drug: Self-administered acupressure
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered acupressure (SAA)
Trial: 35219449
Drug: i.v. ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ketamine (0.3 mg kg−1)
Trial: 35505644
Drug: Tramadol via
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol via patient-controlled analgesia (PCA) pump (600 mg daily)
Trial: 35505644
Drug: Intermittent tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent tramadol administration
Trial: 33570975
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation and treatment-as-usual (TAU)
Trial: 32186656
Drug: Rituximab (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (1000 mg IV on days 0 and 14, 500 mg at months 12 and 18) combined with short-term prednisone regimen
Trial: 32186656
Drug: PDAI score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDAI score of 45 or higher and/or persistent anti-DSG1 or anti-DSG3 antibody values at month 3
Trial: 32878514
Drug: M2000 (mannuronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M2000 (mannuronic acid) 1000 mg/day (two 500 mg capsules daily)
Trial: 32878514
Drug: Conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drug (interferon beta‐1a, interferon beta‐1b)
Trial: 33357709
Drug: HFD +
RxNorm normalized name: Hydrofluorodiethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFD + OCN (3 μg/bird, 1 time/2 d, i.m.)
Trial: 34525277
Drug: BNT162b2 vaccine
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 vaccine (30-µg doses, two doses at 21 days apart)
Trial: 36331844
Drug: Non-cultured epidermal
RxNorm normalized name: omidubicel
DrugBank: Omidubicel (DB17132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-cultured epidermal cell suspension
Trial: 36941575
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care chemotherapy
Trial: 32507144
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative treatment associated with exercises (OMT/EG)
Trial: 37086227
Drug: Colchicine 0.6
RxNorm normalized name: colchicine 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.6 mg orally twice daily for 7 days starting immediately post-procedure (group B)
Trial: 37086227
Drug: Colchicine 0.6
RxNorm normalized name: colchicine 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.6 mg orally twice daily for 7 days (group B)
Trial: 37074705
Drug: Tralokinumab 150
RxNorm normalized name: Tralokinumab 150 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tralokinumab 150 mg
Trial: 34798037
Drug: Etrolizumab 105
RxNorm normalized name: Etrolizumab
DrugBank: Etrolizumab (DB12189)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrolizumab 105 mg subcutaneously once every 4 weeks
Trial: 34798038
Drug: Infliximab 5
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 5 mg/kg intravenously at 0, 2, and 6 weeks, then every 8 weeks for 52 weeks
Trial: 33899093
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (targeted therapy)
Trial: 33683586
Drug: Substrate with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substrate with organic compost (S1) at 50% effluent dose
Trial: 33683586
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment at doses 25% and 50% in S1
Trial: 32283762
Drug: Curcumin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin supplementation (180 mg/day for 12 weeks)
Trial: 32548299
Drug: Tumor Sphericity
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor Sphericity (SPH) at early-treatment (T1)
Trial: 36735054
Drug: Denosumab 60
RxNorm normalized name: denosumab 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 60 mg (Prolia, Amgen Inc.) administered at baseline, 6, and 12 months
Trial: 39131711
Drug: Risankizumab (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab (various doses)
Trial: 35096113
Drug: Ginger (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger (500 mg twice a day)
Trial: 32799397
Drug: Other consumer
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other consumer medication information (CMI) with SMART program
Trial: 32495663
Drug: Multiple-dose GnRH-a
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple-dose GnRH-a
Trial: 32495663
Drug: Single-dose GnRH-a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose GnRH-a
Trial: 32746864
Drug: 0.75% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% bupivacaine with 20 μg of fentanyl (1 ml)
Trial: 32746864
Drug: 0.75% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% bupivacaine with 5 μg of DEX (1 ml)
Trial: 32746864
Drug: 0.75% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% bupivacaine with saline (1 ml)
Trial: 34067240
Drug: Supplementation with
RxNorm normalized name: Similac For Supplementation with Iron Powder for Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementation with Harpagophytum procumbens, Zingiber officinale and Bixa orellana (2 g/day in 6 doses for 4 weeks)
Trial: 35790450
Drug: Montmorency tart
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montmorency tart cherry (MTC) capsules
Trial: 36038585
Drug: Zinc acetate
RxNorm normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc acetate 50 mg × 3 daily
Trial: 36038585
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate 50 mg × 3
Trial: 36038585
Drug: Zinc acetate
RxNorm normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc acetate 150 mg × 1
Trial: 36038585
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate 150 mg × 1
Trial: 33037644
Drug: Education sessions
RxNorm normalized name: Alternanthera sessilis extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education sessions for interns, residents, and clinical pharmacists about appropriate analgesic prescribing.
Trial: 35872697
Drug: Metformin (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (control group)
Trial: 33006602
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of diclofenac etalhyaluronate (DF-HA) intra-articularly at weeks 0, 4, and 8
Trial: 36216432
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (triggered by Hb ≤100 g/L)
Trial: 36216432
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (triggered by Hb ≤70 g/L)
Trial: 33962104
Drug: Target genes
RxNorm normalized name: Genesis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target genes involved in biological pathways
Trial: 33484775
Drug: Elafibranor 80
RxNorm normalized name: elafibranor 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elafibranor 80 mg
Trial: 33314326
Drug: RP3128 (25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RP3128 (25, 50, 100, 200, and 400 mg single doses; 25, 100, and 400 mg once daily for 7 days)
Trial: 34394889
Drug: Shexiang Baoxin
RxNorm normalized name: CAMPHOR (NATURAL) 30.53 mg / MENTHOL 40.71 mg / METHYL SALICYLATE 25.95 mg TOPICAL PLASTER [SheXiang ZhuangGu Gao]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shexiang Baoxin pill (given on the basis of conventional treatment)
Trial: 33172321
Drug: Conventional physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physiotherapy (hot pack therapy, interferential current, myofascial relaxation, cervical dynamic isometric exercises)
Trial: 34557087
Drug: Metamizole 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metamizole 1,000 mg three times daily for 7 days
Trial: 34557087
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg twice daily for 7 days
Trial: 32530733
Drug: Two-dose EV71
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose EV71 vaccination
Trial: 32129511
Drug: Self-administration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration of romiplostim (n = 621)
Trial: 32129511
Drug: HCP administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HCP administration of romiplostim (n = 133)
Trial: 32129511
Drug: Self-administration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration of romiplostim
Trial: 32129511
Drug: HCP administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HCP administration of romiplostim
Trial: 35777773
Drug: F ENO-based
RxNorm normalized name: F-15599
DrugBank: F-15599 (DB16936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F ENO-based asthma management (adjustment of asthma treatment according to exhaled nitric oxide and symptoms every 6-12 weeks)
Trial: 35777773
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (no treatment adjustment as part of the trial)
Trial: 32444994
Drug: BAX602 spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAX602 spray
Trial: 34693688
Drug: Cellex (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cellex (1 ml subcutaneously once daily for 10 days)
Trial: 32663909
Drug: Decoglurant 5
RxNorm normalized name: Decoglurant
DrugBank: Decoglurant (DB11923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decoglurant 5 mg
Trial: 32663909
Drug: Decoglurant 15
RxNorm normalized name: Decoglurant
DrugBank: Decoglurant (DB11923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decoglurant 15 mg
Trial: 32663909
Drug: Decoglurant 30
RxNorm normalized name: Decoglurant
DrugBank: Decoglurant (DB11923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decoglurant 30 mg
Trial: 34840669
Drug: Melatonin 0.5
RxNorm normalized name: melatonin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 0.5 mg/kg once a day, in the morning (MEL group)
Trial: 34817419
Drug: Low-dose control
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose control
Trial: 32144955
Drug: Zanubrutinib 480
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanubrutinib 480 mg
Trial: 32144955
Drug: Zanubrutinib 160
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanubrutinib 160 mg
Trial: 34362445
Drug: 12-month external
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month external implementation intervention including developmental evaluation, on-site visit, and monthly facilitation calls.
Trial: 33338583
Drug: Ashwagandha 300
RxNorm normalized name: Jarrow Formulas Ashwagandha 300 mg Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ashwagandha 300 mg, twice daily, orally for 8 weeks
Trial: 33338583
Drug: Placebo, twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, twice daily, orally for 8 weeks
Trial: 36187084
Drug: EXER (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EXER (loading programme specific to Achilles tendon combined with physical therapy)
Trial: 36187084
Drug: Patient preference
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient preference and satisfaction with treatment
Trial: 34171280
Drug: Pharmacokinetic-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetic-guided treatment group
Trial: 34981324
Drug: Long biliopancreatic
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long biliopancreatic Roux-en-Y gastric bypass (L-RYGB)
Trial: 32592273
Drug: Intra-dermal tranexamic
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-dermal tranexamic acid (TXA) injections
Trial: 33220216
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment with dihydroartemisinin-piperaquine
Trial: 33220216
Drug: Single screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single screening and treatment with dihydroartemisinin-piperaquine
Trial: 36049700
Drug: High-dose MVC-COV1901
RxNorm normalized name: MVC-COV1901
DrugBank: MVC-COV1901 (DB15854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose MVC-COV1901 (25 mcg)
Trial: 36049700
Drug: Mid-dose MVC-COV1901
RxNorm normalized name: MVC-COV1901
DrugBank: MVC-COV1901 (DB15854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mid-dose MVC-COV1901 (15 mcg)
Trial: 34331403
Drug: Nuts (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nuts (50 g day-1)
Trial: 36195982
Drug: Top performing
RxNorm normalized name: Perform Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Top performing text message (described vaccine as 'reserved for you')
Trial: 33460240
Drug: iACT (Internet-delivered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iACT (Internet-delivered acceptance and commitment therapy)
Trial: 32700215
Drug: Community-based diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based diabetes self-management education (DSME) plus 6 months of mHealth-enhanced peer support (12 weekly phone calls, then 3 monthly calls)
Trial: 34835098
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group from a historic randomized controlled trial of ganciclovir for early treatment of CMV infection.
Trial: 33147073
Drug: Wearable respiratory
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wearable respiratory monitor with daily in-application breathing exercise for 30 days
Trial: 32139409
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (6000 mg/day)
Trial: 35484697
Drug: Baricitinib 4
RxNorm normalized name: baricitinib 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 4 mg + TCS
Trial: 32186160
Drug: Acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture therapy (30-minute sessions, 3 times weekly for 6 weeks)
Trial: 32186160
Drug: Routine conventional
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine conventional Western Medicine treatment alone
Trial: 35106617
Drug: TDM-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDM-guided therapy (continuous infusion of piperacillin/tazobactam with dosing guided by daily TDM)
Trial: 35106617
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose therapy (continuous infusion of piperacillin/tazobactam at 13.5 g/24 h if eGFR ≥ 20 mL/min)
Trial: 35106617
Drug: TDM-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDM-guided therapy
Trial: 35106617
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose therapy
Trial: 33909732
Drug: Implant survival
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant survival probability for patients ≤ 70 years of age
Trial: 33248581
Drug: ZnSO4 treatment:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZnSO4 treatment: 80 mg zinc/kg from ZnSO4
Trial: 33248581
Drug: ISO treatment:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISO treatment: 40 mg zinc/kg from ZnSO4 plus 40 mg zinc/kg from a zinc-amino acid complex
Trial: 33248581
Drug: Organic treatment:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Organic treatment: 40 mg zinc/kg from a zinc-amino acid complex
Trial: 32759193
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D 400 IU and 500 mg of calcium carbonate twice a day for 1 year
Trial: 33277370
Drug: GVAX with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GVAX with low-dose oral cyclophosphamide
Trial: 33525212
Drug: SOF/LDP 400/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOF/LDP 400/100 mg daily plus standard of care (n=42)
Trial: 33348685
Drug: 280 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 280 g/day of frozen raspberries for 8 weeks
Trial: 37671748
Drug: Pharmacokinetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetics
Trial: 34837121
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment 14 days prior to surgery
Trial: 35152536
Drug: Intralesional injection
RxNorm normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of vitamin D3 (1ml every 4 weeks for a maximum of 3 sessions)
Trial: 36118833
Drug: Cognitive Behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavior Therapy (CBT) combined with Eye Movement Desensitization and Reprocessing (EMDR)
Trial: 32409691
Drug: isatuximab 3
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: isatuximab 3 mg/kg every 2 weeks (Q2W)
Trial: 32409691
Drug: isatuximab 10
RxNorm normalized name: ISATUXIMAB 100 mg in 5 mL INTRAVENOUS INJECTION, SOLUTION, CONCENTRATE [Sarclisa]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isatuximab 10 mg/kg Q2W/Q4W
Trial: 32409691
Drug: isatuximab 10
RxNorm normalized name: ISATUXIMAB 100 mg in 5 mL INTRAVENOUS INJECTION, SOLUTION, CONCENTRATE [Sarclisa]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isatuximab 10 mg/kg Q2W
Trial: 32409691
Drug: isatuximab 20
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: isatuximab 20 mg/kg QW(1 cycle)/Q2W
Trial: 32409691
Drug: isatuximab (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isatuximab (doses ≥10 mg/kg)
Trial: 32961119
Drug: Nivolumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (3 mg/kg every 2 weeks for four doses, then every 12 weeks until 1 year or until disease recurrence, unacceptable toxicity, or withdrawal)
Trial: 32961119
Drug: Ipilimumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (10 mg/kg every 3 weeks for four doses, then every 12 weeks until 1 year or until disease recurrence, unacceptable toxicity, or withdrawal)
Trial: 36174848
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral once per month for up to 5 years)
Trial: 33977364
Drug: ModelCI (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ModelCI (combination of clinical factors and imaging characteristics)
Trial: 35244287
Drug: Recombinant follicle-stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant follicle-stimulating hormone (rFSH) at doses of 0.5, 1.1, and 2.2 IU/kg/d
Trial: 35244287
Drug: Recombinant follicle-stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant follicle-stimulating hormone (rFSH) at all doses
Trial: 32267573
Drug: Vicagrel (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicagrel (24 mg loading dose, 6 mg maintenance dose)
Trial: 32267573
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg loading dose, 75 mg maintenance dose)
Trial: 33538934
Drug: Video intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Video intervention adjuncts (VIAs) paired with dialectical behavior therapy (DBT) for IPV skills group
Trial: 36975019
Drug: Antihypertensive agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive agents